This study is in progress, not accepting new patients
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Verastem, Inc.
- ID
- NCT05375994
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 85 study participants
- Last Updated